Skip to main contentAI and Advanced
/
ZYDUSWELL · NSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
ZY
NSE · Equity shares · Food Processing1.85 · 0.34%
Zydus Wellness ZYDUSWELL
NSE:INR 551.8
BSE:INR 551.7
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for ZYDUSWELL
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 549.95
Day rangeINR 535.75 — INR 559
52-week rangeINR 357.55 — INR 611.85
Volume1.64 L
Market cap17,059.44
P/E97.99
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)3,961
Net Income (INR Cr)197.2
Rev Growth (5 Year %)16.24
EPS Growth (5 Year %)9.66
P/E Ratio97.99
EPS7.3
Research path: Interpret Zydus Wellness's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ZYDUSWELLZydus Wellness1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 10,307.8 | 6,441.9 | 6,148.4 |
| Accumulated Depreciation Total | -269.4 | -244.9 | -214.4 |
| Other Liabilities Total | 74.3 | 23.4 | 18.3 |
| Accrued Expenses | 21.6 | 14.1 | 15.8 |
| Long Term Debt | 3,034.9 | Not available | Not available |
| Common Stock Total | 63.6 | 63.6 | 63.6 |
| Other Equity Total | -4.5 | -0.3 | 0.2 |
| Other Current Assets Total | 0.4 | 0.4 | 0.4 |
| Prepaid Expenses | 8.8 | 3.1 | 3.3 |
| Total Assets | 10,307.8 | 6,441.9 | 6,148.4 |
| Current Portof LT Debt/Capital Leases | 5.8 | 1.9 | 1.5 |
| Additional Paid-In Capital | 3,537 | 3,537 | 3,537 |
| Cash | 110.6 | 66.7 | 80 |
| Total Equity | 5,826 | 5,671.6 | 5,357.5 |
| Long Term Investments | 0.9 | 0.7 | 0.7 |
| Retained Earnings(Accumulated Deficit) | 2,229.9 | 2,071.3 | 1,756.7 |
| Total Common Shares Outstanding | 31.82 | 31.82 | 31.82 |
| Property/Plant/Equipment Total-Gross | 607.8 | 550.4 | 470.8 |
| Tangible Book Valueper Share Common Eq | -77.15 | 26.31 | 28.18 |
| Goodwill Net | 4,941.9 | 4,010.5 | 3,920 |
| Total Liabilities | 4,481.8 | 770.3 | 790.9 |
| Total Debt | 3,202.8 | 188.3 | 328.7 |
| Short Term Investments | 4.3 | 42.5 | 236 |
| Cashand Short Term Investments | 114.9 | 109.2 | 316 |
| Total Receivables Net | 465.6 | 466.8 | 418.6 |
| Notes Payable/Short Term Debt | 150 | 185 | 324 |
| Deferred Income Tax | 632 | Not available | Not available |
| Accounts Receivable-Trade Net | 383.8 | 367 | 283.3 |
| Property/Plant/Equipment Total-Net | 338.4 | 305.5 | 256.4 |
| Total Current Liabilities | 728.5 | 745.5 | 769.4 |
| Total Inventory | 777 | 524.7 | 476 |
| Accounts Payable | 461.4 | 428.8 | 362.9 |
| Other Currentliabilities Total | 89.7 | 115.7 | 65.2 |
| Total Long Term Debt | 3,047 | 1.4 | 3.2 |
| Intangibles Net | 3,338.7 | 824 | 540.8 |
| Other Long Term Assets Total | 127.6 | 149.3 | 195.8 |
| Note Receivable-Long Term | 193.6 | 47.7 | 20.4 |
| Total Current Assets | 1,366.7 | 1,104.2 | 1,214.3 |
| Capital Lease Obligations | 12.1 | 1.4 | 3.2 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %42.22
Margins
Operating Margin 12m7.83
Operating Margin 5y Avg11.75
Net Profit Margin 12m4.15
Net Profit Margin 5y10.78
Yield
Dividend Yield %0.23
Valuation
Price to Sale Ratio4.31
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk42.49
Analyst consensus
ConsensusStrong Buy
Consensus score1.57
Analyst opinions7
Strong Sell count0
Sell count0
Hold count1
Buy count2
Strong Buy count4
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Nestle India | INR 1,500 | 2.89 L | 80.4 | — |
| Britannia Industries | INR 5,430 | 1.31 L | 51.47 | — |
| Godrej Industries | INR 1,307.9 | 44,269.32 | 34.92 | — |
| Tata Consumer Products | INR 1,090 | 1.08 L | 67.4 | — |
| Patanjali Foods | INR 355 | 38,627.86 | 18.91 | — |
Shareholding
Ownership
- Promoter
- 69.64%
- FII
- 3.32%
- MF
- 18.73%
- Other
- 8.31%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
True North cashes out $2 billion for investors as PE firms step up exitsMarket news · 6 Jul 2026, 11:17 am
This comes on the back of exits for True North from portfolio firms like FedFina, Niva Bupa, Biocon Biologics, Infinity Fincorp Solutions, Zydus Wellness and Home First Finance.
Zydus Wellness sees more of price-led growth as costs surgeMarket news · 19 May 2026, 4:35 pm
Rising input costs and acquisition-led expansion are reshaping the growth strategy at Zydus Wellness. Rising inflation may push it to rely more on price-led growth, signalling broader pressure on consumer-facing firms as the impact of the West Asia war spreads across the economy.
Mint Interview | Ignore the noise, focus on consumers, says Zydus Wellness CEO amidst stock rallyMarket news · 14 Apr 2026, 2:16 pm
Shares of the company have jumped 25% in the last month despite posting losses in the last two quarters but its CEO Tarun Arora is nonchalant about it — instead is focused on staying ahead of consumer expectations. In this interview, Arora talks of his outlook for the company and new businesses.
Top Gainers & Losers on April 06: Zydus Wellness, Trent, Gravita India, RBL Bank, BSE NMDC among top gainersMarket news · 6 Apr 2026, 3:46 pm
On April 6, the Indian stock market reversed early losses, fueled by a ceasefire plan between Iran and the U.S. The Nifty 50 and Sensex each rose over 1%, with Zydus Wellness seeing a significant 15% spike in shares, the largest in 17 years.
Zydus Wellness rallied on the Comfort Click deal. Has the excitement faded?Market news · 19 Dec 2025, 3:22 pm
After acquiring UK-based Comfort Click for ₹ 2,380 crore, Zydus’ stock surged. The move expands its global wellness footprint, but near-term profitability pressures remain.
Stock to buy: Zydus Wellness share price rallies 15% in 3 days; Anand Rathi sees more upside. Details hereMarket news · 3 Sept 2025, 3:05 pm
Zydus Wellness shares increased nearly 4% to reach a 52-week high of ₹ 2,336.90 on September 3. The stock has risen over 15% in three sessions following its subsidiary's acquisition of UK-based Comfort Click Limited.
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.2000 per share(60%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- splitsStock split from Rs. 10/- to Rs. 2/-.
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Zydus Wellness
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Zydus Wellness Limited operates as an integrated consumer company. It is engaged in development, production, marketing and distribution of health and wellness products. Its portfolio spans category- food and nutrition brands: RiteBite Max Protein, Complan, Sugar Free, Sugar Free D’Lite, I’m Lite, Glucon-D and Nutralite; dietary supplement brands, including WeightWorld and MaxMedix; pet care brand Animigo; and skincare brands like Everyuth and Nycil. Glucon-D is a glucose powder brand. Glucon-D is available in regular flavors of Tangy Orange & Nimbu Pani. Complan is a nutritional drink designed for growing school children and contains 34 vital nutrients along with 100% milk protein to support growth. Nycil is a prickly heat and cooling powder brand. It offers skin care products under the brand name of Everyuth Naturals. It has four manufacturing facilities across three locations - Aligarh, Ahmedabad and Sikkim. It has 18 co-manufacturing facilities in India, UAE, and New Zealand.
Company facts
- Industry
- Food Processing
- Sector
- Food Processing
- NSE Code
- ZYDUSWELL
- BSE Code
- 531335
Questions
Stock FAQ
What is the symbol and ISIN of Zydus Wellness?
Zydus Wellness has the symbol ZYDUSWELL and ISIN - INE768C01028.
What is the current price of Zydus Wellness?
Zydus Wellness is currently trading at INR 551.80.
What are the year high and year low of Zydus Wellness?
Zydus Wellness has a year high of INR 611.85 and a year low of INR 357.55.
What is the market capitalization of Zydus Wellness?
Zydus Wellness has a market capitalization of INR 17,059.44 crore.
What is the P/E ratio of Zydus Wellness?
Zydus Wellness has a P/E ratio of 97.99.
What is the dividend yield of Zydus Wellness?
Zydus Wellness has a dividend yield of 0.23%.
How is the financial performance of Zydus Wellness based on revenue, net income, and EPS?
Zydus Wellness has revenue of INR 3,961.00 crore, net income of INR 197.20 crore, and EPS of INR 6.71.
What is the book value of Zydus Wellness?
Zydus Wellness has a book value of NA.
What is the debt-to-equity ratio of Zydus Wellness?
Zydus Wellness has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Zydus Wellness?
Zydus Wellness has a price-to-book ratio of NA and a price-to-sales ratio of 4.31.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.